×

Nexvet Biopharma plc (Nasdaq: NVET) to Ring The Nasdaq Stock Market Closing Bell

ADVISORY, Nov. 23, 2015 (GLOBE NEWSWIRE) --

What:
Nexvet Biopharma plc (Nasdaq:NVET), a global, clinical-stage, veterinary biologics developer, will visit the Nasdaq MarketSite in Times Square to celebrate the successful completion of a pivotal study for NV-01, its biologic therapy in development for the control of pain associated with osteoarthritis in dogs.

In honor of the occasion, the co-founders of Nexvet, Dr. Mark Heffernan, Chief Executive Officer and Dr. David Gearing, Chief Scientific Officer, will ring the Closing Bell.

Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:
Monday, November 23, 2015 – 3:45 p.m. to 4:00 p.m. ET

Nexvet Biopharma plc Media Contact:
David Salisbury
Berry & Company Public Relations
(212) 253-8881
dsalisbury@berrypr.com

Nasdaq MarketSite:
Will Briganti
(646) 441-5012
William.Briganti@nasdaq.com

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page:
http://instagram.com/nasdaq

For news tweets, please visit our Twitter page at:
http://twitter.com/nasdaq

For exciting viral content and ceremony photos visit Tumblr Page:
http://nasdaq.tumblr.com/

Webcast:
A webcast of the Nasdaq Closing Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About Nexvet Biopharma plc (Nasdaq:NVET):
Nexvet is a veterinary biologics developer focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet's proprietary PETization™ platform is designed to rapidly design monoclonal antibodies ("mAbs") that are recognized as "self" or "native" by an animal's immune system, a property Nexvet refers to as "100% species-specificity." Nexvet's product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost. Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, which conducts drug discovery in Australia, clinical development in the United States and Europe and is growing its biomanufacturing capabilities in Ireland.

About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of approximately $8.8 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

-NDAQA-

Source:NASDAQ, Inc.